Pro-Dex, Inc.
$53.3
▲
1.33%
2026-04-21 08:47:00
www.pro-dex.com
NCM: PDEX
Explore Pro-Dex, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$174.44 M
Current Price
$53.3
52W High / Low
$70.26 / $23.47
Stock P/E
15.38
Book Value
$12.97
Dividend Yield
—
ROCE
22.96%
ROE
30.87%
Face Value
—
EPS
$3.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
179
Beta
-0.11
Debt / Equity
27.41
Current Ratio
4.03
Quick Ratio
1.71
Forward P/E
24.99
Price / Sales
2.33
Enterprise Value
$167.64 M
EV / EBITDA
13.3
EV / Revenue
2.33
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Bionano Genomics, Inc. | $1.31 | — | $14.53 M | — | -65.83% | -66.15% | $5.5 / $1.06 | $4.14 |
| 2. | Sharps Technology, Inc. | $1.84 | — | $73.85 M | — | -452.36% | -2.03% | $18.23 / $1.42 | $15.68 |
| 3. | ResMed Inc. | $224.49 | 22.19 | $32.69 B | 1.06% | 23.58% | 25.68% | $293.81 / $202 | $43.39 |
| 4. | AngioDynamics, Inc. | $10.79 | — | $449.55 M | — | -11.8% | -17.47% | $13.99 / $8.36 | $4.16 |
| 5. | Jin Medical International Ltd. | $2.08 | 13.77 | $16.4 M | — | 2.06% | 4.75% | $19.7 / $1.64 | $3.79 |
| 6. | Merit Medical Systems, Inc. | $69.79 | 32.83 | $4.22 B | — | 7.59% | 8.67% | $100.19 / $66.34 | $26.66 |
| 7. | NEXGEL, Inc. | $0.64 | — | $6.98 M | — | -41.75% | -52.74% | $2.99 / $0.56 | $0.64 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 18.66 M | 18.53 M | 17.49 M | 17.41 M | 16.79 M |
| Operating Profit | 3.26 M | 3.11 M | 1.34 M | 3.64 M | 2.69 M |
| Net Profit | 2.19 M | 4.68 M | 1.2 M | 3.27 M | 2.04 M |
| EPS in Rs | 0.68 | 1.46 | 0.37 | 1.02 | 0.64 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 66.59 M | 53.84 M | 46.09 M | 42.04 M |
| Operating Profit | 10.69 M | 7.17 M | 5.76 M | 5.16 M |
| Net Profit | 8.98 M | 2.13 M | 7.07 M | 4.57 M |
| EPS in Rs | 2.8 | 0.66 | 2.21 | 1.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.19 M | 52.48 M | 51.82 M | 49.09 M |
| Total Liabilities | 24.56 M | 21.61 M | 20.23 M | 23.66 M |
| Equity | 36.63 M | 30.87 M | 31.59 M | 25.43 M |
| Current Assets | 47.3 M | 36.61 M | 30.98 M | 31.17 M |
| Current Liabilities | 14.63 M | 12.89 M | 9.68 M | 11.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -1.68 M | 6.22 M | 5.46 M | -0.85 M |
| Investing CF | -0.24 M | -2.23 M | -0.89 M | -1.24 M |
| Financing CF | -0.29 M | -4.3 M | -2.49 M | -0.79 M |
| Free CF | -2.93 M | 5.24 M | 4.49 M | -2.52 M |
| Capex | -1.25 M | -0.98 M | -0.97 M | -1.67 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 16.83% | 9.62% | — | — |
| Earnings Growth % | -69.93% | 54.72% | — | — |
| Profit Margin % | 3.95% | 15.35% | 10.88% | — |
| Operating Margin % | 13.32% | 12.5% | 12.27% | — |
| Gross Margin % | 27.02% | 27.66% | 31.24% | — |
| EBITDA Margin % | 8.08% | 23.47% | 16.37% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.